- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07410117
REGN7508 för vuxna deltagare för prevention av cancerassocierad trombos (ROXI-CAT-I)
En fas 3, multicenter, randomiserad, dubbelblind, placebokontrollerad studie för att utvärdera effekt och säkerhet hos REGN7508, en monoklonal antikropp mot FXI, för primär profylax av cancerassocierad trombos för deltagare med solida tumörer som genomgår cancerbehandling (ROXI-CAT-I)
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Clinical Trials Administrator
- Telefonnummer: 844-734-6643
- E-post: clinicaltrials@regeneron.com
Studieorter
-
-
Florida
-
Hialeah, Florida, Förenta staterna, 33013
- Rekrytering
- Bioresearch Partner- Hialeah Hospital
-
North Miami Beach, Florida, Förenta staterna, 33169
- Rekrytering
- Helios Clinical Research
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Rekrytering
- Beth Israel Deaconess Medical Center
-
-
New York
-
New York, New York, Förenta staterna, 10021
- Rekrytering
- Memorial Sloan Kettering Cancer Center
-
-
Texas
-
El Paso, Texas, Förenta staterna, 79902
- Indragen
- El Paso Medical Research Institute (Medresearch Inc)
-
-
-
-
-
Tbilisi, Georgien, 0159
- Rekrytering
- Institute of Clinical Oncology
-
Tbilisi, Georgien, 0186
- Rekrytering
- Caucasus Medical Centre
-
Tbilisi, Georgien, 0144
- Rekrytering
- Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
-
Tbilisi, Georgien, 0179
- Rekrytering
- LTD Cancer Research Centre
-
Tbilisi, Georgien, 0179
- Rekrytering
- JSC Evex Hospitals - Caraps Medline
-
Tbilisi, Georgien, 0102
- Rekrytering
- American Hospital Tbilisi
-
Tbilisi, Georgien, 0112
- Rekrytering
- Llc Todua Clinic
-
Tbilisi, Georgien, 0112
- Rekrytering
- Israel Georgia Medical Research Clinic Helsicore
-
-
Adjara
-
Batumi, Adjara, Georgien, 6000
- Rekrytering
- LTD High Technology Hospital Medcenter
-
-
Imereti
-
Kutaisi, Imereti, Georgien, 4600
- Rekrytering
- Krystyna Kiel Oncology Center
-
-
-
-
-
Niigata, Japan, 951-8520
- Rekrytering
- Niigata University Medical & Dental Hospital
-
-
Ehime
-
Tōon, Ehime, Japan, 791-0295
- Rekrytering
- Ehime University Hospital
-
-
Gunma
-
Ōta, Gunma, Japan, 373-8550
- Rekrytering
- Gunma Prefectural Cancer Center
-
-
Hyōgo
-
Akashi, Hyōgo, Japan, 673-8558
- Rekrytering
- Hyogo Cancer Center
-
-
Kagawa-ken
-
Kita-gun, Kagawa-ken, Japan, 761-0793
- Rekrytering
- Kagawa University Hospital
-
-
Kanagawa
-
Isehara-Shi, Kanagawa, Japan, 259-1193
- Rekrytering
- Tokai University Hospital
-
-
Kyoto
-
Kyoto, Kyoto, Japan, 602-8566
- Rekrytering
- University Hospital Kyoto Prefectural University of Medicine
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-8574
- Rekrytering
- Tohoku University Hospital
-
-
Osaka
-
Chuo, Osaka, Japan, 540-0006
- Rekrytering
- National Hospital Organization Osaka National Hospital (ONH)
-
-
Saitama
-
Ina-machi, Saitama, Japan, 362-0806
- Rekrytering
- Saitama Cancer Center
-
-
Tokyo
-
Chuo Ku, Tokyo, Japan, 104-0045
- Rekrytering
- National Cancer Center Hospital - Tsukiji Campus
-
Shinjuku, Tokyo, Japan, 160-0023
- Rekrytering
- Tokyo Medical University Hospital
-
-
Yamaguchi
-
Ube, Yamaguchi, Japan, 755-8505
- Rekrytering
- Yamaguchi University Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol
- Has a Khorana thromboembolic risk score ≥2 during screening period or harbors a somatic documented tumor genetic variant known to be associated with a similar increased risk of VTE as described in the protocol
- Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study intervention
Key Exclusion Criteria:
- Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy)
- Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma
- Has a primary brain tumor or brain metastases as described in the protocol
- Has proximal lower extremity DVT locally detected by Compression Ultrasound (CUS) during screening period
- Has any condition that, as judged by the investigator, may confound the results of the study or would place the participant at increased risk of harm if he/she participated in the study
Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Placebo
|
Administered per the protocol |
|
Experimentell: REGN7508
|
Administered per the protocol
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Tid till första händelsen av centralt bedömd International Society of Thrombosis and Hemostasis (ISTH) större blödning eller kliniskt relevant icke-större (CRNM) blödning
Tidsram: Under 6 månader
|
Under 6 månader
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related death
Tidsram: Through 6 months
|
Through 6 months
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Förekomst av behandlingsrelaterade biverkningar (TEAEs)
Tidsram: Upp till dag 245
|
Upp till dag 245
|
|
Allvarlighetsgrad av TEAEs
Tidsram: Upp till dag 245
|
Upp till dag 245
|
|
Magnituden av ADA till REGN7508
Tidsram: Upp till dag 245
|
Upp till dag 245
|
|
Time-to-first event of the centrally adjudicated symptomatic or incidental VTE (DVT, PE) or ATE and thromboembolism- or ATE-related death
Tidsram: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic VTE
Tidsram: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic DVT
Tidsram: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic non-fatal PE
Tidsram: Through 6 months
|
Through 6 months
|
|
Time-to-first event of thromboembolism-related death
Tidsram: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental VTE
Tidsram: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental upper extremity or incidental proximal lower extremity DVT
Tidsram: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental non-fatal PE (in a segmental or larger pulmonary artery)
Tidsram: Through 6 months
|
Through 6 months
|
|
Time-to-first event of asymptomatic VTE (Asymptomatic DVT detected by lower extremities ultrasound)
Tidsram: Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE
Tidsram: Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE-related death
Tidsram: Through 6 months
|
Through 6 months
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE), or thromboembolism-related death
Tidsram: Through 6 months
|
Through 6 months
|
|
Occurrence of Anti-Drug Antibody (ADA) to REGN7508
Tidsram: Up to day 245
|
Up to day 245
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Clinical Trial Management, Regeneron Pharmaceuticals
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- R7508-CAT-2392
- 2024-519298-21-00 (Ctis)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Tidsram för IPD-delning
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Kriterier för IPD Sharing Access
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
- ANALYTIC_CODE
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .